


UCB7362

Cat. No.:	HY-151568
CAS No.:	3031484-59-7
Molecular Formula:	C ₂₅ H ₂₆ ClN ₅ O ₃
Molecular Weight:	479.96
Target:	Parasite
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	UCB7362 is an orally active and potent antimalarial plasmepsin X (PMX) inhibitor, with an IC ₅₀ of 7 nM. UCB7362 inhibits parasite growth ^[1] .	
IC₅₀ & Target	Plasmodium	
In Vitro	<p>UCB7362 is substantially more potent against PMX than PMIX with an IC₅₀ of 7 nM for the former compared to 142 nM for the latter^[1].</p> <p>UCB7362 also demonstrates an improvement in selectivity against Cat D and Renin with an IC₅₀ of 3889 nM and >10,000 nM, respectively^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
In Vivo	<p>UCB7362 (10-60 mg/kg, Oral administration, twice a day, for 4 days) clears parasitemia from peripheral blood^[1].</p> <p>UCB7362 (IV (1 mg/kg), PO (10 mg/kg); once) shows moderate clearance in dog and cynomolgus monkey and moderate-high in rat^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>	
	Animal Model:	Pf (Plasmodium falciparum) SCID mouse model ^[1]
	Dosage:	10, 25 and 60 mg/kg
	Administration:	Oral administration, twice a day, for 4 days, with the second administration 10 h after the first one
	Result:	Cleared parasitemia from peripheral blood in a dose-dependent manner.
	Animal Model:	Sprague Dawley rat ^[1]
	Dosage:	1 mg/kg, 10 mg/kg
	Administration:	IV (1 mg/kg), PO (10 mg/kg); once (Pharmacokinetic Analysis)
	Result:	Pharmacokinetic Parameters of UCB7362 in Sprague-Dawley rats ^[1] .

	IV (1 mg/kg)	PO (10 mg/kg)
CL (mL/(min kg))	43.9	
V _{ss} (L/kg)	5.72	
T _{max} (h)		3
C _{max} (nM)		246
AUC ₀₋₂₄ (nM⋅h)	793	1410
t _{1/2} (h)	2.1	
F (%)		11

REFERENCES

[1]. Lowe MA, et al. Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmeprin X Inhibitors and Preclinical Safety Assessment of UCB7362. J Med Chem. 2022 Oct 10.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA